Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIRA-B: Dose-Ranging Study of Pegylated Interferon Lambda in HBeAg-positive Chronic Hepatitis B
2010-020387-38Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of peginterferon lambda-1a in Chronic Hepatitis B (CHB), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of pegylated interferon lambda, Antiviral activity: HBV DNA suppression and 1 more. Started Oct 2010; status: completed.
02
Drugs
peginterferon lambda-1a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2010-020387-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020387-38.